Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) will report fourth quarter and full year 2025 financial results and host a conference call on Thursday, February 26, 2026 at 5:00 PM ET.
Investors can join via live webcast on the company’s Investors page or by telephone after registering in advance; a replay will be posted on the Investors page.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EBS declined 1.63%, reflecting a mild negative market reaction. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $570M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Drug Manufacturers - Specialty & Generic showed mixed moves, with KMDA up 1.79%, ETON up 4.9%, and EOLS, CGC, SIGA down between 0.9% and 3.59%, indicating EBS trading is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Product approval | Positive | +3.0% | FDA approved supplemental NDA for new NARCAN® Nasal Spray carrying case. |
| Jan 12 | Debt reduction | Positive | -4.4% | Voluntary prepayment of <b>$100 million</b> on term loan, reducing gross debt. |
| Jan 08 | Government contract | Positive | -3.0% | Delivery order up to <b>$21.5 million</b> for BioThrax® anthrax vaccine supply. |
| Jan 08 | Clinical support | Positive | -3.9% | Additional backing for Africa CDC-led MOSA mpox study with no safety concerns. |
| Jan 07 | Conference presentation | Positive | +5.7% | Announcement of presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
Recent positive operational and financial news has often seen mixed to negative immediate price reactions, with more divergence than alignment.
Over the past month, Emergent BioSolutions announced multiple constructive developments, including FDA approval for new NARCAN® packaging, a $100 million voluntary term loan paydown, and a U.S. Department of War delivery order up to $21.5 million for BioThrax®. The company also supported the Africa CDC-led MOSA mpox study and presented at the 44th Annual J.P. Morgan Healthcare Conference. Despite these updates, price reactions have alternated between gains and selloffs, providing a mixed backdrop as the company approaches its Q4 and full-year 2025 earnings call date.
Market Pulse Summary
This announcement sets a clear timetable for Emergent BioSolutions’ review of Q4 and full-year 2025 results on February 26, 2026 at 5:00 pm ET. Investors can contextualize upcoming numbers against recent FDA approval, government contract wins, and debt reduction moves highlighted in prior releases. Key items to watch include balance sheet progress, operational performance across product lines, and any updated strategic commentary during the conference call webcast.
AI-generated analysis. Not financial advice.
GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025.
Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When will Emergent BioSolutions (EBS) report Q4 and full year 2025 results and hold the conference call?
How can investors access the Emergent BioSolutions (EBS) February 26, 2026 conference call?
What is required to join the Emergent BioSolutions (EBS) conference call by telephone on February 26, 2026?
Will there be a replay of the Emergent BioSolutions (EBS) February 26, 2026 earnings call?
Where can I find registration and dial-in information for the Emergent BioSolutions (EBS) earnings call?
